Short Interest in Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Drops By 10.2%

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) was the recipient of a large drop in short interest during the month of November. As of November 30th, there was short interest totalling 1,517,000 shares, a drop of 10.2% from the November 15th total of 1,688,500 shares. Based on an average daily volume of 100 shares, the days-to-cover ratio is presently 15,170.0 days.

Swedish Orphan Biovitrum AB (publ) Stock Performance

Shares of BIOVF stock opened at $28.62 on Tuesday. The business has a 50 day simple moving average of $29.57 and a 200 day simple moving average of $28.12. The company has a debt-to-equity ratio of 0.30, a current ratio of 0.73 and a quick ratio of 0.49. The firm has a market capitalization of $8.45 billion, a price-to-earnings ratio of 48.51 and a beta of 0.51. Swedish Orphan Biovitrum AB has a 12-month low of $22.40 and a 12-month high of $32.25.

Swedish Orphan Biovitrum AB (publ) Company Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.